News
UTHR
235.07
+1.42%
3.29
United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating
United Therapeutics (UTHR) was revisited by a Wall Street analyst yesterday. Analyst Roanna Ruiz from Leerink Partners maintained a Buy rating on the stock and has a $335.00 price target. The analyst is focusing on the company’s Tyvaso therapies.
TipRanks · 3h ago
Implied PBUS Analyst Target Price: $56
NASDAQ · 2d ago
Weekly Report: what happened at UTHR last week (0408-0412)?
Weekly Report · 2d ago
S&P 500 Futures Up In Premarket Trading; Halozyme Therapeutics, Revvity Lead
U.S. Stock markets are set to open in two hours. Stocks in Asia were up overnight. Brent crude oil futures were up 0.29%. Bitcoin was down 1.22% to $70,798. The S&P 500 and the Dow were down overnight.
Barron‘s · 04/09 11:31
Weekly Report: what happened at UTHR last week (0401-0405)?
Weekly Report · 04/08 09:15
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
United Therapeutics has grown its earnings per share (EPS) by 22% per year in the last three years. The company is growing its revenue by 20% to US$2.3b. It has a history of growing earnings and revenue, but is growing at a slower rate than the market. United Therapeutic's CEO pay is modest compared to the median CEO pay of US$13m. We believe the company is worth a look at because of its strong earnings growth. United Therapedutics has been buying up shares in recent years.
Simply Wall St · 04/05 16:33
S&P 500 Futures Drop In Premarket Trading; PVH Corp., Humana Lag
U.S. Stock markets are set to open in two hours. Stocks in Asia were mixed overnight. Bitcoin fell 6.54% to $65,158. Brent crude oil futures were up 1.38% and gold futures up 0.86%. The S&P 500 and the Dow were down in early trading.
Barron‘s · 04/02 11:31
BUZZ-Liquidia Corp rises on plans to seek full approval for blood disorder drug
Liquidia Corp said it can seek full approval for its blood pressure drug. Shares of drug developer rise 7.5% to $15.85 premarket. U.S. District court of Delaware set aside the patent infringement lawsuit. Drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension.
Reuters · 04/01 12:24
Weekly Report: what happened at UTHR last week (0325-0329)?
Weekly Report · 04/01 09:14
United Therapeutics motion for restraining order over Liquidia's Yutrepia denied
United Therapeutics motion for restraining order over Liquidia's Yutrepia denied by a judge. The FDA can approve the drug for high blood pressure in the lungs as early as March 31. The court victory sent Liquidia Corporation's shares up 5% in after-hours trading.
Seeking Alpha · 03/31 12:00
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)
TipRanks · 03/29 07:20
Liquidia gains after court win in patent dispute with United Therapeutics
Liquidia Corporation (LQDA) rose 4% in after hours trading after a win in a patent dispute with United Therapeutics. US District Judge granted Liquidia's post-judgement relief. Liquidia soared 36% on Dec. 20 after a court victory in its Patent dispute with UTHR.
Seeking Alpha · 03/28 20:24
BUZZ-Liquidia falls as rival Merck's therapy for lung condition gets FDA approval
Liquidia falls as rival Merck's therapy for lung condition gets FDA approval. Shares of Liquidia LQDA.O fall ~5.7% to $15.01. Merck treatment for adults with pulmonary arterial hypertension (PAH) approved late on Tuesday.
Reuters · 03/27 14:39
Merck hits all-time high after FDA nod for lung disease therapy
Merck's pulmonary arterial hypertension drug Winrevair approved by FDA. The drug was added as part of the company's $11.5B acquisition of Acceleron in 2021. Johnson & Johnson, the current leader in the PAH drug market, traded flat.
Seeking Alpha · 03/27 13:50
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
NASDAQ · 03/27 12:39
S&P 500 Futures Up In Premarket Trading; Revolution Medicines, Robinhood Markets Lead
U.S. Stock markets set to open in two hours. S&P 500 futures were up 0.42% in pre-market trading. Stocks in Asia were mixed overnight. Brent crude oil futures were down 0.55% in commodities news. Bitcoin was up 1% to $70,105.
Barron‘s · 03/27 11:31
Merck wins FDA approval of sotatercept for rare lung disease
U.S. FDA has approved Merck's sotatercept for pulmonary arterial hypertension, a rare type of lung disease. The drug will cost $14,000 per vial without insurance. Merck shares are up 5% in after-hours trading.
Seeking Alpha · 03/26 21:48
12 Health Care Stocks Moving In Tuesday's After-Market Session
Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The company's, Q4 earnings came out today. Cara Therapeutics shares moved upwards by 7.36% and Iridex stock increased by 5.52%. Losers Akili and Mira Pharmaceuticals were the biggest losers in the market.
Benzinga · 03/26 21:32
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)
United Therapeutics, Regeneron and Intuitive Surgical are among the top 3 Healthcare stocks recommended by analysts. 3 analysts have issued bullish reports on the stocks. Wells Fargo, Bernstein and Stifel Nicolaus have each assigned a Buy rating to the companies. The analysts are bullish on the Healthcare sector.
TipRanks · 03/26 08:51
United Therapeutics Announces $1 Billion Stock Buyback Plan
TipRanks · 03/25 21:12
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.